Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval

Apr 1, 2024 11:26 am | News

Chronic Obstructive Pulmonary Disease COPD Concept


Sanofi (NASDAQ:SNY) and Regeneron Pharmaeuticals (NASDAQ:REGN) Dupixent (dupiliumab), already a blockbuster drug approved for several indications, including asthma and eosinophilic esophagitis, is poised for further gains as it is likely to gain approval for chronic obstructive pulmonary disease.

Dupixent sales could

feed from